Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
5 drugs in development
By Therapeutic Area
top 1
R&D Momentum
64/100
Pipeline Velocity
37/100
Trial Completion Rate
100/100
Pipeline Concentration
100/100
Pipeline Freshness
68/100
Activity
Last 14 days
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma
Study on the Incidence and Risk Factors of Systemic Arterial Gas Embolism in Bronchoscopy Procedures
A Single-Center, Randomized, Open-Label, Single-Dose, Four-Period, Two-Sequence, Fully Replicated Crossover Bioequivalence Study of Rivaroxaban 2.5 mg Tablets in Healthy Adult Participants Under Fasting and Fed Conditions
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)